Andrew Schiermeier
Chief Executive Officer presso AvenCell Therapeutics, Inc.
Profilo
Andrew D. Schiermeier è nel consiglio di amministrazione di Kynan Pharmaceuticals e direttore operativo di Intellia Therapeutics, Inc. Nella sua carriera passata ha occupato la posizione di Chief Operating Officer presso Aura Biosciences, Inc. e Senior CP & Head-Oncology Business presso Merck KGaA. Ha ricevuto un MBA dal College des Ingenieurs, un dottorato dalla Harvard University e una laurea alla Stanford University.
Posizioni attive di Andrew Schiermeier
| Società | Posizione | Inizio |
|---|---|---|
| Kynan Pharmaceuticals | Director/Board Member | - |
AvenCell Therapeutics, Inc.
 AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Chief Executive Officer | 01/08/2021 |
Regel Therapeutics Inc.
 Regel Therapeutics Inc. BiotechnologyHealth Technology Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020. | Director/Board Member | - |
Precedenti posizioni note di Andrew Schiermeier
| Società | Posizione | Fine |
|---|---|---|
| INTELLIA THERAPEUTICS, INC. | Chief Operating Officer | 21/06/2021 |
| MERCK KGAA | Corporate Officer/Principal | 01/01/2016 |
| AURA BIOSCIENCES, INC. | Chief Operating Officer | 01/05/2013 |
Formazione di Andrew Schiermeier
| Harvard University | Doctorate Degree |
| Stanford University | Graduate Degree |
| College des Ingenieurs | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| MERCK KGAA | Health Technology |
| AURA BIOSCIENCES, INC. | Health Technology |
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
| Kynan Pharmaceuticals | |
AvenCell Therapeutics, Inc.
AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Health Technology |
Regel Therapeutics Inc.
Regel Therapeutics Inc. BiotechnologyHealth Technology Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020. | Health Technology |
- Borsa valori
- Insiders
- Andrew Schiermeier
